

The 17th Japanese Foundation for Cancer Research International Symposium on Cancer Chemotherapy

New Antitumor Agents under Development in the US, Europe and Japan

December 5 - 6, 2012

Miraikan

(National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan



December 5, Wed 13:00-16:30

Opening remark **Mitsuaki Yoshida**
(Cancer Chemotherapy Center)

I Patient Selection Strategies in Early Clinical Studies

13:10-14:30 Chairpersons: **Anthony W. Tolcher**,
Atsushi Ohtsu

Jaap Verweij (Erasmus University Medical Center): The future of early clinical trials in new drug development

Toshio Shimizu (Kinki University): Personalizing cancer treatment of targeting of PI3K/AKT/mTOR pathway in patients with advanced cancer

II Companion Diagnostics

14:30-15:30 Chairpersons: **Gregory K. Pennock**,
Yoshikazu Sugimoto

Mark J. Ratain (The University of Chicago): Companion diagnostics: Consideration of tumor heterogeneity

Kengo Takeuchi (Cancer Institute, JFCR): Discovery of fusion genes by histomolecular pathology

Poster Session

15:30-16:30

December 6, Thu 9:00-17:40

III Cancer Cell Line Panels for Drug Screening

9:00-10:20 Chairpersons: **Michael Kahn**, **Toshimitsu Uenaka**

Cyril H. Benes (MGH Cancer Center): Systematic identification of genomic markers of drug sensitivity in cancer cells

Takao Yamori (PMDA, Japan): JFCR39 cell line panel

Poster Discussion Session

10:20-11:50

Chairperson: **Shiro Akinaga**
Mentor: **Dr. Jaap Verweij**
Dr. Mark Ratain
Dr. Keith T. Flaherty

Luncheon Seminar I 12:00-12:45

Chairpersons: **Akihiko Tsuruoka**

Bruce A. Littlefield (Oncology PCU, Eisai Inc.):
Preclinical discovery, pharmacology, and mechanism of eribulin

Luncheon Seminar II 12:00-12:45

Chairpersons: **Toshimitsu Uenaka**

Felix Garzon (Oncology PCU, Eisai Inc.):
Clinical development of eribulin

Registration Deadline at 9:00, October 31, 2012.

Registration Fee 40,000 yen
Free for Student

Contact: Cancer Chemotherapy Center,
Japanese Foundation for Cancer Research
jfcrcr-iscc@ml.jfcr.or.jp

Special Lecture 13:00-13:40

Jeffrey A. Engelman (MGH Cancer Center):

Resistance to EGFR-TKI in lung cancer

Chairperson: **Tetsuichiro Muto**

IV Revival of Immune Response or BRAF Inhibition for Cancer Therapy

13:40-15:10 Chairpersons: **Keith T. Flaherty**, **Ryuzo Ueda**

Gregory K. Pennock (MD Anderson Cancer Center):
Ipilimumab: A novel immunopotentiator

Keith T. Flaherty (MGH Cancer Center): BRAF inhibition as a basis for building combination targeted therapy in melanoma and other cancers

V Targeting FGFR Pathway

15:10-16:20 Chairpersons: **Jeffrey A. Engelman**, **Saburo Sone**

Ken Kobayashi (Janssen Pharmaceutical K.K.):
FGFR tyrosine kinase inhibitor

Anthony W. Tolcher (START, San Antonio): Targeting FGR ligands in cancer with the FGF Trap FP 1039

VI New Drugs under Clinical Trials

16:20-17:30 Chairpersons: **Cyril H. Benes**, **Shunji Takahashi**

Glenn Begley (TetraLogic Pharmaceuticals): IAP binding peptide (Birinapant (TL32711)(SMAC mimetics))

Michael Kahn (University of Southern California): Pharmacologic manipulation of stem cells and cancer stem cells

Closing remark **Jaap Verweij**
(Erasmus University Medical Center)

<http://iscc.umin.jp/>